Gijon (Spain) and Guimarães (Portugal) – September 19th, 2019
Gistem Research SL and Stemmatters SA announced today that they have entered a collaborative project to assess the potential of a novel stem cell-derived therapy for the treatment of distal ulcerative colitis and anal fistulas.
Under the terms of the agreement, Gistem and Stemmaters will assess the safety and efficacy profile of the hUCESC´s secretome formulated by Stemmatters in preclinical studies. In case of successful results, both companies agreed to further pursue drug development.
Rui Sousa, CEO of Stemmatters, added “this is a great opportunity to collaborate in an exciting area of therapeutic development and large unmet medical need. We look forward to leveraging the therapeutic potential of GISTEM technology through our know-how and expertise in design and formulation of combination products”.
“We are pleased to initiate this collaboration with Stemmatters where we hope to develop therapies that can potentially advance the standard of care of patients suffering from ulcerative colitis and anal fistulas”, said Francisco Vizoso, Gistem´s founder.
GiStem Research (Gijon, Spain) is a privately-owned company developing innovative therapies derived from their proprietary human Uterine Cervical Stem Cells (hUCESCs) platform, a novel source of mesenchymal stem cells showing facile cell isolation protocol, high manufacturing process scalability, and immunoregulatory activity. More information available at: http://www.gistemresearch.com
Stemmatters, SA (Guimarães, Portugal) is an integrated biotechnology company that develops and manufactures novel biological and advanced therapy products. The company implements has expertise in design and formulation of new combination products, for which Stemmatters can implement and assure GMP-compliant manufacturing for first-in-human clinical studies or commercial supply programs. For company information, please visit: http://www.stemmatters.com/
Phone: +34 984 991 074